Ascendiant Capital Markets Forecasts Strong Price Appreciation for Allarity Therapeutics (NASDAQ:ALLR) Stock

Allarity Therapeutics (NASDAQ:ALLR) had its price target boosted by equities researchers at Ascendiant Capital Markets from $9.25 to $9.50 in a report released on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the stock.

Other analysts have also issued research reports about the stock. Wall Street Zen upgraded shares of Allarity Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, September 20th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Allarity Therapeutics in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Allarity Therapeutics presently has a consensus rating of “Hold” and an average price target of $9.50.

Allarity Therapeutics Stock Down 1.3%

Shares of Allarity Therapeutics stock traded down $0.02 on Tuesday, reaching $1.15. 236,553 shares of the stock were exchanged, compared to its average volume of 2,910,387. The business has a 50 day moving average price of $1.35 and a two-hundred day moving average price of $1.22. The firm has a market capitalization of $18.09 million, a price-to-earnings ratio of -1.93 and a beta of 0.23. Allarity Therapeutics has a twelve month low of $0.61 and a twelve month high of $2.35.

Allarity Therapeutics (NASDAQ:ALLR) last issued its quarterly earnings results on Friday, November 14th. The company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.04. Research analysts forecast that Allarity Therapeutics will post -78.08 EPS for the current year.

Institutional Trading of Allarity Therapeutics

Institutional investors have recently bought and sold shares of the business. Private Advisor Group LLC purchased a new stake in shares of Allarity Therapeutics in the third quarter valued at approximately $441,000. Citadel Advisors LLC acquired a new stake in Allarity Therapeutics in the 3rd quarter valued at $149,000. XTX Topco Ltd purchased a new stake in Allarity Therapeutics in the 2nd quarter worth $51,000. Geode Capital Management LLC increased its holdings in Allarity Therapeutics by 49.3% in the 2nd quarter. Geode Capital Management LLC now owns 50,650 shares of the company’s stock worth $51,000 after acquiring an additional 16,729 shares in the last quarter. Finally, Jane Street Group LLC acquired a new position in Allarity Therapeutics during the second quarter worth $27,000. 11.53% of the stock is owned by institutional investors and hedge funds.

About Allarity Therapeutics

Allarity Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme.